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PTPN22 gene polymorphism in Takayasu’s arteritis
N. Sahin1, K. Aksu2, S. Kamalı3, M. Bicakcigil1, Z. O¨zbalkan4, I. Fresko5, H. O¨zer6, S. Akar7,
A. M. Onat8, V. C¸obankara9, S. Kiraz10, M. A. O¨ztu¨rk11, E. Tunc¸12, E. Yu¨cel13, A. Ates 4, G. Keser2,
M. Inanc3, H. Direskeneli1 and G. Saruhan-Direskeneli14 for RAED Vasculitis Study Group, Turkey
Objective. Takayasu’s arteritis (TA) is a chronic, rare granulomatous panarteritis of unknown aetiology involving mainly the aorta and
its major branches. In this study, genetic susceptibility to TA has been investigated by screening the functional single nucleotide
polymorphism (SNP) of PTPN22 gene encoding the lymphoid-specific protein tyrosine phosphatase.
Methods. Totally, 181 patients with TA and 177 healthy controls are genotyped by PCR-RFLP method for the SNP rs2476601 (A/G)
of PTPN22 gene. Polymorphic region was amplified by PCR and digested with Xcm I enzyme.
Results. Detected frequencies of heterozygous genotype (AG) were 5.1% (9/177) in control group and 3.8% (7/181) in TA group (P¼ 0.61,
odds ratio: 0.75, 95% CI: 0.3, 2.0). No association with angiographic type, vascular involvement or prognosis of TA was observed either.
Conclusion. The distribution of PTPN22 polymorphism did not reveal any association with TA in Turkey.
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Introduction
Takayasu’s arteritis (TA), also known as pulseless disease, is a
chronic granulomatous panarteritis characterized by the involve-
ment of large vessels, especially the aorta and its major branches
[1]. Cellular immunity may play the major role in disease
pathogenesis as involved vessels are infiltrated mainly by 
T cells, NK cells, cytotoxic T cells, Th1 cells and macrophages [2].
Previous studies showed an elevated ratio of CD4/CD8T cells,
increased number of HLA-DRþ circulating lymphocytes and
markedly increased 65-kDa HSP expression in tissues along with
the presence of  T cells [3]. Infections, autoimmunity and genetic
factors are implicated in the pathogenesis of TA. Evidences of
genetic susceptibility to TA have also been demonstrated in
several studies. Especially, associations of TA with HLA-B52 and
-B39 have been reported previously from Japan, whereas HLA-B5
was associated with TA in India [4, 5].
Lymphoid-specific protein tyrosine phosphatase (LYP) is
encoded on chromosome 1p13 at PTPN22 gene and a single
nucleotide polymorphism (SNP) of the gene has been demonstrated
to be associated with several autoimmune disorders [6, 7]. LYP is
involved in maintaining the resting phenotype of lymphocytes and
in controlling signalling caused by an antigen, co-stimulation and
cytokines [8]. The PTPN22 gene polymorphism causing an amino
acid change (R620W) at the proline-rich motif of LYP has been
shown to affect the protein–protein interaction with tyrosine
kinase Csk in T-cell activation. Individuals carrying the variant
allele of PTPN22 are suggested to have changes in the threshold for
thymic selection with increased numbers of auto-reactive T cells
escaping negative selection and be prone to autoimmunity.
However, the mechanism of action remains to be clarified, as
both gain and loss of function mechanisms have been reported
[7, 9, 10]. An association of PTPN22 R620W polymorphism
(rs2476601, A/G) was reported first with type 1 diabetes [11] and
later also with myasthenia gravis [12], SLE [13] and RA [9].
However, there are also some inflammatory diseases such as IBD,
psoriasis, multiple sclerosis, AS [6] and Behcet’s disease (BD) [14]
with no association of this polymorphism.
PTPN22 R620W polymorphism reveal a wide variation in allele
frequencies among different populations, polymorphic allele being
present highest in Scandinavia (15%), whereas is absent in Asian
and African populations [15, 16]. Considering this spectrum of the
diseases and variations among populations, we investigated the
possible association of PTPN22 polymorphism with TA in this
study.
Materials and methods
The study was designed as a case–control study enrolling 181
patients with TA (19 men, 162 women; mean age: 37 11.7 yrs).
Patients were classified according to the 1990 ACR criteria for the
classification of TA [17]. Angiographic classification is done as
proposed by the International Cooperative Study on TA in 1997
[18]. According to this classification, 39% (n¼ 70) of the patients
had type 1 vessel involvement, 8.2% type 2a (n¼ 15), 1.1% type
2b (n¼ 2), 3.3% type 3 (n¼ 6), 4.4% type 4 (n¼ 8) and 44% type 5
(n¼ 80). As controls, 177 healthy blood donors (86 men, 91
women; mean age: 40 9.7 yrs) were recruited. All patients and
controls were enrolled with local ethics committee approval and
provided their informed consent.
Genotyping
For genotyping, cellular DNA was isolated from 10ml of
peripheral blood using standard procedures. For the determina-
tion of PTPN22 alleles, PCR-based restriction fragment length
polymorphism (RFLP) analysis was performed. DNA was
amplified using the forward primer 50GGC CTC AAT GAA
CTC CTC AA 30 and reverse primer 50AAT GTT GCT TCA
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ACG GAA TTT 30. PCR amplification was carried out in
1 (NH4) buffer with 2mM MgCl2, 200M dNTP, 0.4M of
each primer, 100 ng of genomic DNA and 0.75 IU of Taq
polymerase within a final volume of 30l. The cycling parameters
were as follows: initial denaturation step of 2min at 958C; 30
cycles of 30 s at 958C, 45 s at 598C, 45 s at 728C and final extension
step of 2min at 728C.
The polymorphism was identified by XcmI digestion for 4 h at
378C. Variant allele (A) was cut into 163 and 166 bp fragments
and the digest (329 bp) was run on 3% agarose gel stained with
ethidium bromide.
Statistical analysis
Genotype frequencies were compared between patients and
control groups by chi-square test. The post hoc power analysis
was performed using the statistical program PowerSamplesize
assuming ¼ 0.05 and small effect size of 0.1 (http://biostat.mc.
vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize).
Results
When the distribution of the polymorphism is evaluated in the
healthy population, genotype frequencies were in Hardy–
Weinberg equilibrium. The frequency of heterozygous genotype
(AG) was 5% (9/177) in the control group and this was
corresponding to an allele frequency of 0.025. The homozygous
AA genotype was not present in this control group. In TA
patients, polymorphic A allele was only detected in 7 out of 181
patients as a heterozygote genotype AG (3.8%). There was no
statistically significant difference between TA and control group
according to the frequency of heterozygote genotype (P¼ 0.61,
odds ratio: 0.75, 95%CI: 0.3, 2.0). AG genotype was not
associated with angiographic type, vascular involvement or
prognosis of TA. Post hoc analysis revealed a power of 83%
with the assumed low effect size in this sample.
Discussion
Pathophysiology of TA is not exactly known but is thought to be
multifactorial involving infectious agents (Mycobacterium tuber-
culosis, different types of viruses), autoimmunity and genetic
influences [2]. Since cell-dependent autoimmunity may play a
major role in pathogenesis, we investigated polymorphism of
PTPN22 gene which is repeatedly shown to be associated with
different autoimmune diseases and considered as one of the most
common markers of susceptibility to autoimmunity [6]. However,
in our study, no significant difference between TA and control
group is observed, suggesting that LYP does not influence the
pathogenesis of TA.
Our previous study in BD, another systemic disorder with
autoimmune features, did also not reveal any association with
PTPN22 gene polymorphism [14]. An important factor in genetic
studies is the ethnic heterogeneity and there are ethnic differences
regarding the frequencies of PTPN22 polymorphism in different
populations. In Turkey, it is somewhat lower compared with the
other Caucasian populations (5%). Considering previous findings
on similarities of the Turkish population with the other European
data, this was unexpected. However, low frequencies of this
polymorphism have also been reported in populations such as
Japanese and Mexican. Absence of a TA-PTPN22 association
may also be related to this low prevalence and may not rule out an
association in other, especially Caucasian, populations.
Another explanation for our results may be the lack of
autoimmune features in TA. Although clinical spectrum of TA
such as low-grade, continuous inflammation causing a long,
generally unremitting disease course and tissue-infiltrating cell
types such as T cells suggest the involvement of cell-mediated
immunity, TA lacks some other autoimmune phenomena such as
the presence of autoantibodies (ANA) and co-existence with other
autoimmune disorders such as multiple sclerosis or type 1
diabetes. Granulomatous panarteritis is also uncommon in
autoimmune diseases such as SLE. In this respect, it is interesting
to note that PTPN22 is found to be associated with WG, but not
with GCA [19, 20]. Although both disorders are accepted to be
granulomatous vasculitides, WG patients also have ANCA and
have medium-size vessel involvement with neutrophil infiltrations,
whereas GCA have more resemblance to TA such as large-vessel-
confined vasculitis without classical autoantibodies.
As a conclusion, a role of PTPN22 R620W polymorphism
could not be demonstrated in TA pathogenesis. Low prevalence of
this polymorphism in Turkey or pathogenetic differences with the
classic autoimmune disorders may account for this result.
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Rheumatology key message
 PTPN22 R620W polymorphism is found to be unassociated with
TA in Turkey.
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